[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know",
    "summary": "Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=94c799e215366d598b008f3dd6c2c0dd0007432e678a2a68e4d3f798d52483fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743717010,
      "headline": "Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know",
      "id": 133704897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=94c799e215366d598b008f3dd6c2c0dd0007432e678a2a68e4d3f798d52483fe"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).",
    "url": "https://finnhub.io/api/news?id=f5fd93fd56e5b7b9ca7623b8b7214c2216284672bd9de69eac3336dd31fb19d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743671314,
      "headline": "Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks",
      "id": 133697756,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).",
      "url": "https://finnhub.io/api/news?id=f5fd93fd56e5b7b9ca7623b8b7214c2216284672bd9de69eac3336dd31fb19d3"
    }
  }
]